Nxera Pharma (SOLTF) to Announce Quarterly Earnings on Friday

Nxera Pharma (OTCMKTS:SOLTF) is expected to be issuing its resultson Friday, August 7th. Analysts expect the company to post earnings of ($0.0217) per share and revenue of $52.1190 million for the quarter.

Nxera Pharma Price Performance

OTCMKTS SOLTF opened at $5.73 on Thursday. The firm’s fifty day simple moving average is $6.09 and its two-hundred day simple moving average is $5.96. Nxera Pharma has a 12-month low of $4.90 and a 12-month high of $7.94.

Nxera Pharma Company Profile

Nxera Pharma Co, Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company’s development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders.